EDP-305 Targets NASH in Phase 2 Trial Testing Two Doses Against Placebo
Enanta Pharmaceuticals tests its FXR agonist EDP-305 in a completed Phase 2 randomized trial for non-alcoholic steatohepatitis.
20 articles
Enanta Pharmaceuticals tests its FXR agonist EDP-305 in a completed Phase 2 randomized trial for non-alcoholic steatohepatitis.
A completed trial investigates whether replenishing glutathione precursors can reverse metabolic dysfunction in elderly adults.
A Phase IIa trial explores whether the HIF-PHI drug daprodustat can safely replace EPO injections in hemodialysis patients with anemia.
A sponsored 90-day trial of enhanced-absorption quercetin targeting cholesterol, blood sugar, and metabolic age was terminated before completion.
A Phase 2 trial tests a GalNAc-conjugated antisense therapy in familial partial lipodystrophy patients with dangerously high triglycerides.
Maastricht University investigated whether NA, NAM, and tryptophan together could restore mitochondrial function in physically compromised older adults.
New study reveals how endurance exercise transforms fat-burning brown adipose tissue in just six weeks of training.
275-patient study tests novel liver-targeted therapy for NASH, a serious form of fatty liver disease affecting millions worldwide.
Takeda's Phase 1 trial evaluates the safety and tolerability of TAK-510, a novel injectable agent targeting nausea and vomiting, across escalating doses.
Stanford study tests whether GLP-1 drug exenatide can restore insulin function and promote weight loss in people with prediabetes.
Phase 4 trial tests whether alirocumab can better control non-HDL cholesterol in high-risk type 2 diabetics failing statin therapy.
Researchers mapped how anesthetics, nitric oxide, and other drugs alter hemoglobin's grip on oxygen โ with real implications for critical care.
A completed Danish trial investigates how blocking IL-6 signaling with tocilizumab alters fat, glucose, and protein metabolism in humans.
Carmot Therapeutics tests CT-868, a novel dual incretin receptor agonist, for HbA1c reduction in overweight and obese adults with poorly controlled T2DM.
New research suggests extending overnight fasting from 10 to 16 hours may enhance muscle's ability to use dietary protein for growth.
French study reveals how aging influences metabolic responses to cancer, potentially explaining malnutrition patterns in elderly patients.
Duke study shows high-quality egg protein combined with calorie restriction improves metabolic outcomes in older adults with prediabetes.
176-person trial tested whether pioglitazone could improve liver health by targeting insulin resistance in patients with fatty liver disease.
Major trial of 10,251 diabetics reveals surprising outcomes from aggressive blood sugar, blood pressure, and cholesterol management.
A completed University of Michigan trial explored how aerobic exercise training alters RAGE-mediated inflammatory pathways in type 2 diabetic adults.